Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Korean Phase II/III Study To Begin Soon
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
